Skip to main content

Table 2 Investigation of predictors of improvement in respiratory function

From: Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP

 

A%FEV1 < 3.8% (n = 32)

A%FEV1 > 3.8% (n = 18

p value

AERD (no/yes)

19/13

11/7

0.9043

FeNO (ppb),(mean ± SD)

47 (39)

76 (52)

0.0295

IgE, IU/mL (mean ± SD)

232 (198)

625 (753)

0.0133

Blood eosinophil count, cells/uL(mean ± SD)

398 (493)

509 (394)

0.4171

Asthma control test, (mean ± SD)

23.1 (3.5)

23.33 (1.7)

0.7606

Treatment step (GINA),(mean ± SD)

2.3 (1.2)

3.1 (1.1)

0.0336

Preoperative eosinophil count in the nasal polyps(mean ± SD)

153 (231)

128 (46)

0.6703

CT score of sinusitis, (mean ± SD)

12.8 (5.0)

14.6 (4.9)

0.2073

Visual analogue scale 29, (mean ± SD)

7.5 (1.7)

7.3 (2.1)

0.7536

  1. *p < 0.05, **p < 0.01 by unpaired t test or chi-square test